S. Qin

发表

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life with first-line pembrolizumab for PD-L1–positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study

S. Shah, S. Stein, C. Fuchs, 2021, ESMO open.

Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.

K. Muro, Y. Cheng, S. Qin, 2021, ESMO open.

VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

A. Zhu, T. Yau, L. Rimassa, 2021, Annals of Oncology.

IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)

M. Kudo, P. Galle, M. Ducreux, 2019, Annals of Oncology.

A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate–prednisone

Krishna R. Kalari, Liang Wang, K. Kalari, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma.

D. Chakrabarti, M. Casey, M. Kudo, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.

Y. Yen, G. Bhattacharyya, S. Choo, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

P. Galle, Ruifeng Xu, J. Llovet, 2022, Annals of Oncology.

Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT].

R. Finn, F. Piscaglia, L. Wyrwicz, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

M. Lowery, L. Wyrwicz, F. Rivera, 2023, Annals of Oncology.

LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

S. Qin, Y. Bai, M. Pazgan-Simon, 2022, Annals of Oncology.

LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

R. Finn, L. Wyrwicz, E. Assenat, 2022, Annals of Oncology.

IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)

M. Ducreux, A. Cheng, S. Qin, 2021, Zeitschrift für Gastroenterologie.

Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC).

J. Kim, K. Rau, C. Yen, 2018, Annals of Oncology.

1223P First-line lenvatinib (Len) + pembrolizumab (Pembro) + chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in

E. Van Cutsem, Y. Janjigian, L. Wyrwicz, 2022, Annals of Oncology.

56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)

H. Burris, A. Avallone, S. Qin, 2022, Annals of Oncology.

1008P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC

M. Kudo, P. Galle, M. Ducreux, 2020 .

Atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150.

R. Finn, A. Cheng, S. Qin, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.

B. Han, G. Jiang, H. Pan, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1–positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

S. Shah, S. Stein, E. Van Cutsem, 2019, Annals of Oncology.

LBA61 HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC)

Z. Chen, S. Qin, G. Wang, 2022, Annals of Oncology.

68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)

V. Guthrie, S. Qin, D. Tougeron, 2022, Annals of Oncology.